Review



generative tensorial reinforcement learning (gentrl) ai  (Insilico Medicine)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Insilico Medicine generative tensorial reinforcement learning (gentrl) ai
    Applications of AI-based methods at different stages of a drug discovery pipeline. There are about 2700 known potential drug target proteins in the human body and about 9600 FDA-approved small molecule drugs , , . Machine learning can be used to identify the targeted protein, GNNs can be used for predicting drug-target interactions and binding affinity, and <t>reinforcement</t> learning can be used to optimize the properties of a molecule. Computer vision can determine the spatial state of the tumor microenvironment. <t>Generative</t> models can be employed to design new molecules, simulation-based studies can suggest properties of protein-drug complexes, such as stability and dynamics, and NLP can be used to mine the existing scientific literature for drug re-purposing, FDA review, and post-market analysis.
    Generative Tensorial Reinforcement Learning (Gentrl) Ai, supplied by Insilico Medicine, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/generative+tensorial+reinforcement+learning+%28gentrl%29+ai/pmc10302550-417-2-0?v=Insilico+Medicine
    Average 90 stars, based on 1 article reviews
    generative tensorial reinforcement learning (gentrl) ai - by Bioz Stars, 2026-08
    90/100 stars

    Images

    1) Product Images from "AI in drug discovery and its clinical relevance"

    Article Title: AI in drug discovery and its clinical relevance

    Journal: Heliyon

    doi: 10.1016/j.heliyon.2023.e17575

    Applications of AI-based methods at different stages of a drug discovery pipeline. There are about 2700 known potential drug target proteins in the human body and about 9600 FDA-approved small molecule drugs , , . Machine learning can be used to identify the targeted protein, GNNs can be used for predicting drug-target interactions and binding affinity, and reinforcement learning can be used to optimize the properties of a molecule. Computer vision can determine the spatial state of the tumor microenvironment. Generative models can be employed to design new molecules, simulation-based studies can suggest properties of protein-drug complexes, such as stability and dynamics, and NLP can be used to mine the existing scientific literature for drug re-purposing, FDA review, and post-market analysis.
    Figure Legend Snippet: Applications of AI-based methods at different stages of a drug discovery pipeline. There are about 2700 known potential drug target proteins in the human body and about 9600 FDA-approved small molecule drugs , , . Machine learning can be used to identify the targeted protein, GNNs can be used for predicting drug-target interactions and binding affinity, and reinforcement learning can be used to optimize the properties of a molecule. Computer vision can determine the spatial state of the tumor microenvironment. Generative models can be employed to design new molecules, simulation-based studies can suggest properties of protein-drug complexes, such as stability and dynamics, and NLP can be used to mine the existing scientific literature for drug re-purposing, FDA review, and post-market analysis.

    Techniques Used: Drug discovery, Binding Assay



    Similar Products

    generative tensorial reinforcement learning (gentrl) ai  (Insilico Medicine)
    90
    Insilico Medicine generative tensorial reinforcement learning (gentrl) ai
    Applications of AI-based methods at different stages of a drug discovery pipeline. There are about 2700 known potential drug target proteins in the human body and about 9600 FDA-approved small molecule drugs , , . Machine learning can be used to identify the targeted protein, GNNs can be used for predicting drug-target interactions and binding affinity, and <t>reinforcement</t> learning can be used to optimize the properties of a molecule. Computer vision can determine the spatial state of the tumor microenvironment. <t>Generative</t> models can be employed to design new molecules, simulation-based studies can suggest properties of protein-drug complexes, such as stability and dynamics, and NLP can be used to mine the existing scientific literature for drug re-purposing, FDA review, and post-market analysis.
    Generative Tensorial Reinforcement Learning (Gentrl) Ai, supplied by Insilico Medicine, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/generative+tensorial+reinforcement+learning+%28gentrl%29+ai/pmc10302550-417-2-0?v=Insilico+Medicine
    Average 90 stars, based on 1 article reviews
    generative tensorial reinforcement learning (gentrl) ai - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Applications of AI-based methods at different stages of a drug discovery pipeline. There are about 2700 known potential drug target proteins in the human body and about 9600 FDA-approved small molecule drugs , , . Machine learning can be used to identify the targeted protein, GNNs can be used for predicting drug-target interactions and binding affinity, and reinforcement learning can be used to optimize the properties of a molecule. Computer vision can determine the spatial state of the tumor microenvironment. Generative models can be employed to design new molecules, simulation-based studies can suggest properties of protein-drug complexes, such as stability and dynamics, and NLP can be used to mine the existing scientific literature for drug re-purposing, FDA review, and post-market analysis.

    Journal: Heliyon

    Article Title: AI in drug discovery and its clinical relevance

    doi: 10.1016/j.heliyon.2023.e17575

    Figure Lengend Snippet: Applications of AI-based methods at different stages of a drug discovery pipeline. There are about 2700 known potential drug target proteins in the human body and about 9600 FDA-approved small molecule drugs , , . Machine learning can be used to identify the targeted protein, GNNs can be used for predicting drug-target interactions and binding affinity, and reinforcement learning can be used to optimize the properties of a molecule. Computer vision can determine the spatial state of the tumor microenvironment. Generative models can be employed to design new molecules, simulation-based studies can suggest properties of protein-drug complexes, such as stability and dynamics, and NLP can be used to mine the existing scientific literature for drug re-purposing, FDA review, and post-market analysis.

    Article Snippet: Insilico Medicine developed Generative Tensorial Reinforcement Learning (GENTRL) AI, a system that can discover and successfully test new compounds in 46 days, making the whole process 15 times faster .

    Techniques: Drug discovery, Binding Assay